Discontinuation of Antihypertensive Therapy

Clinical Scenarios Warranting Discontinuation

When home blood pressure monitoring consistently shows diastolic BP <80 mm Hg, antihypertensive medications can be withdrawn, according to the American College of Cardiology and the European Society of Hypertension 1, 2
In patients with heart failure with reduced ejection fraction (HFrEF) experiencing symptomatic low BP, a structured down-titration algorithm should be followed rather than complete cessation, as recommended by the European Heart Failure Association 3
For patients with eGFR <30 ml/min/1.73 m², the European Heart Failure Association provides a specific hierarchy for medication reduction, starting with reducing or stopping RAS inhibitors (ACE inhibitors/ARBs/ARNIs) 3
In acute ischemic stroke, pre-existing antihypertensive medications should be temporarily discontinued or reduced during the acute phase (first 24 hours), as recommended by the American Heart Association 4
Hypertension induced by bevacizumab typically resolves after treatment completion, warranting medication reassessment, according to the British Journal of Cancer 5

Critical Warnings About Abrupt Discontinuation

Beta-blockers pose the highest risk and should never be stopped abruptly, as recommended by the American Heart Association, due to the risk of rebound tachycardia, severe hypertension, and precipitation of angina or myocardial infarction 6, 4

Patients at Highest Risk from Discontinuation

Patients with severe baseline hypertension (SBP ≥180 mm Hg or DBP ≥110 mm Hg) should not stop antihypertensive therapy, as recommended by the American Heart Association 4
Patients with pre-existing cardiovascular disease should not stop antihypertensive therapy, as recommended by the American Heart Association 4

Monitoring After Discontinuation

When discontinuation is appropriate, implement structured follow-up, including reassessing BP within 2-4 weeks of stopping medication and using home BP monitoring to detect white coat effect versus true hypertension, as recommended by the European Society of Hypertension and the American College of Cardiology 1, 2, 5
Monitor annually even after successful discontinuation, as recommended by the British Journal of Cancer 5

Common Pitfalls to Avoid

Avoid stopping all medications simultaneously - taper one at a time if multiple agents are being discontinued, as recommended by the European Heart Failure Association 3
Do not discontinue therapy based solely on office BP readings - confirm with home monitoring to rule out white coat hypertension, as recommended by the European Society of Hypertension and the American College of Cardiology 1, 2

Consequences of Stopping Antihypertensive Medications

Drug-Specific Withdrawal Effects

The American College of Cardiology notes that beta-blockers can cause rebound tachycardia, increased blood pressure, and potentially precipitate angina or myocardial infarction in patients with underlying coronary artery disease 7, 8
The American College of Cardiology also reports that clonidine and central alpha-agonists may cause dangerous rebound hypertension with headache, agitation, and tremor within 24-72 hours 8
The American College of Cardiology states that ACE inhibitors/ARBs generally have fewer acute withdrawal symptoms but can lead to gradual blood pressure elevation 8
The European Society of Cardiology notes that calcium channel blockers can cause reflex tachycardia and blood pressure elevation if discontinued rapidly 9

Long-Term Consequences

The American Medical Association found that loss of cardiovascular protection increases the risk of myocardial infarction, stroke, and heart failure 10
The American Medical Association also reports that increased risk of cardiovascular events occurs, especially in patients with pre-existing cardiovascular disease 11, 12
The American Heart Association notes that potential accelerated target organ damage, including cardiac, renal, and cerebrovascular complications, can occur 7
The American Heart Association states that patients with uncontrolled hypertension have higher perioperative risk of cardiovascular disease, cerebrovascular events, and bleeding 7

Risk Factors for Severe Withdrawal Reactions

The American College of Cardiology identifies severe baseline hypertension (SBP ≥180 mm Hg or DBP ≥110 mm Hg) as a risk factor for severe withdrawal reactions 7, 8
The European Society of Cardiology notes that older age and longer duration of hypertension are also risk factors for severe withdrawal reactions 9

Special Populations

The American College of Cardiology recommends continuing antihypertensive therapy throughout the perioperative period for most patients 7
The American College of Obstetricians and Gynecologists states that careful management of antihypertensive discontinuation is critical in pregnant women, as severe hypertension increases risks to both mother and fetus 13
The European Society of Cardiology notes that elderly patients may be more sensitive to abrupt blood pressure changes and at higher risk for falls and orthostatic hypotension during medication adjustments 9

Patient Education

The American College of Cardiology recommends that patients be educated about potential withdrawal symptoms and when to seek medical attention 8

Discontinuation of Antihypertensive Medication in Well-Controlled Hypertension

Indications for Discontinuation

The American College of Cardiology recommends that patients with well-controlled hypertension who wish to discontinue medication should have their blood pressure monitored closely, with immediate restart of medication if systolic BP ≥140 mm Hg or diastolic BP ≥90 mm Hg on home monitoring 14
The Journal of the American College of Cardiology suggests that discontinuation of antihypertensive medication should only be considered in patients with mild hypertension, no target organ damage, and specific favorable characteristics, with careful monitoring for symptoms such as headache, chest pain, or visual changes 15

Management of Discontinuation

The American College of Cardiology guidelines recommend that patients who discontinue antihypertensive medication should be monitored annually indefinitely, even if blood pressure remains controlled, to prevent loss of cardiovascular protection and accelerated target organ damage 14
The Journal of the American College of Cardiology suggests that medication tapering should be done gradually, with one medication tapered at a time, and never stopping beta-blockers or clonidine abruptly, to avoid rebound tachycardia, severe hypertension, and potential precipitation of angina or myocardial infarction 15

Discontinuing Blood Pressure Medications in Specific Clinical Scenarios

Perioperative Management and Special Considerations

The American College of Cardiology recommends continuing beta-blockers and avoiding stopping on the day of surgery, especially in patients with coronary artery disease, to prevent rebound tachycardia and severe hypertension 16
In patients with heart failure with reduced ejection fraction (HFrEF), the European Society of Cardiology advises against completely discontinuing guideline-directed medical therapy (GDMT) even with low blood pressure, and instead recommends reducing or stopping non-GDMT medications first, then reducing RAS inhibitors if necessary 17
The American College of Cardiology also suggests considering holding ACE inhibitors/ARBs 24 hours before surgery to reduce the risk of intraoperative hypotension, and never abruptly stopping clonidine or beta-blockers perioperatively 16
Most hypotension in HFrEF trials was not attributable to medications, and the American College of Cardiology recommends considering whether symptoms truly warrant discontinuation, as stated in JACC: Heart Failure 18

Discontinuation Hierarchy and Tapering

The American College of Cardiology recommends tapering beta-blockers over 7-10 days minimum to prevent rebound tachycardia, severe hypertension, and potential myocardial infarction or angina, especially in patients with coronary artery disease 16

Guidelines for Discontinuing Antihypertensive Therapy (ESC 2024)

Patient Selection for Consideration of Discontinuation

In highly selected adults who have achieved blood‑pressure control through weight loss, sodium intake < 2 g/day, a DASH‑style diet, and regular exercise, a trial of medication reduction may be contemplated. 19

Absolute Contraindications to Stopping Therapy

Diabetes mellitus or chronic kidney disease constitute contraindications to antihypertensive discontinuation. 19
A 10‑year ASCVD risk ≥ 10 % also precludes stopping therapy. 19

Post‑Taper Monitoring Protocol

After any medication taper, home blood‑pressure measurements should be performed twice daily for the first 2 weeks, followed by monthly clinic visits for the next 3 months to detect rebound hypertension. 19
Annual reassessment of overall cardiovascular risk is required even when blood pressure remains controlled without medication. 19

Role of Lifestyle Modification

Although lifestyle changes are essential, they alone are insufficient for most patients to maintain long‑term blood‑pressure control without pharmacologic therapy. 19

ESC 2024 Guideline Recommendations

The European Society of Cardiology (ESC) 2024 guidelines state that when hypertension is confirmed (clinic BP ≥ 140/90 mmHg), both lifestyle interventions and antihypertensive drugs should be initiated together and continued indefinitely. 19
The ESC notes that while successful lifestyle modification may permit dose reduction, complete discontinuation of antihypertensive medication is rarely appropriate in routine clinical practice. 19